February 07, 2026 09:35 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Big call from RBI: Repo rate stays at 5.25%, neutral stance continues | RG Kar scam twist: Court issues non-bailable warrant against whistle-blower Akhtar Ali | Court snub for Vijay: Madras HC rejects plea in ₹1.5 crore tax case | ‘We never said no’: Suryakumar Yadav says India ready for Pakistan clash at T20 World Cup | Supreme Court orders Mamata govt to clear pending dues | ‘India is free to buy oil from anyone’: Russia fires back at Trump’s crude deal claim | ‘Justice crying behind closed doors’: Mamata Banerjee slams ECI in Supreme Court, CJI Kant assures solution | Mummy, Papa, sorry: Three sisters jump to death after parents object to online gaming | Supreme Court raps Meta, WhatsApp: ‘Theft of private information, won’t allow its use’ | ‘Completely surrendered’: Congress slams Modi after Trump’s trade deal move
Covishield
Image tweeted by @adarpoonawalla

Covishield ready to roll out in coming weeks: SII CEO Adar Poonawalla

| @indiablooms | Jan 03, 2021, at 09:11 pm

New Delhi/UNI: Hours after the Drugs Controller General of India (DGCI) approved Oxford-AstraZeneca COVID-19 vaccine ''Covishield'' for restricted emergency use, Serum Institute of India (SII) CEO Adar Poonawalla announced that the vaccine is ready to roll out in the coming weeks.

"Happy new year, everyone! All the risks @SerumInstIndia took with stockpiling the vaccine, have finally paid off. COVISHIELD, India's first COVID-19 vaccine is approved, safe, effective and ready to roll-out in the coming weeks," Poonawalla tweeted.

He further expressed gratitude to Prime Minister Narendra Modi and Union Health Minister Dr HarshVardhan, among others for extending their support.

"Thank you Hon. Sri @narendramodi Ji, Hon. Sri @drharshvardhan Ji, @MoHFW_INDIA @ICMRDELHI @DBTIndia #DCGI_India @UniofOxford @AstraZeneca @gavi @GaviSeth @gatesfoundation and @BillGates for your support," Poonawalla said.

The pharmaceutical giant had on December 7 sought an emergency use authorisation for its Covishield coronavirus vaccine from the Drugs Controller General of India.

Experts say the Covishield vaccine is logistically feasible for distribution in urban and rural parts as it can be stored at two to eight degrees Celsius, which is an ideal temperature for being kept in cold storages in the country.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.